SCHEMBL3737820

SCHEMBL3737820

CC(C)C(C(=O)NCc1ccc(C[N+](C)(C)CCF)o1)n1cc(-c2ccc(S(N)(=O)=O)cc2)nn1.Cc1ccc(S(=O)(=O)[O-])cc1

nearest known ligand 0.56

Known targets — ChEMBL curated mechanism

CHRM1CHRM2CHRM3CHRM4CHRM5SLC6A2dacAdacBdacCftsImrcAmrcBmrdA

The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CA2 P00918 14/20 0.56
CA9 Q16790 13/20 0.56
CA1 P00915 11/20 0.56
CA12 O43570 9/20 0.56
CA14 Q9ULX7 5/20 0.56
CA4 P22748 5/20 0.56
CA5A P35218 4/20 0.56
CA5B Q9Y2D0 4/20 0.56
CA3 P07451 3/20 0.56
CA6 P23280 3/20 0.56
CA7 P43166 3/20 0.56
CA13 Q8N1Q1 3/20 0.56
PTGS2 P35354 3/20 0.37
HDAC8 Q9BY41 1/20 0.32
KMT2A Q03164 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3737816 1.00 CA2 (0.56) CA2CA9CA1CA12CA14
SCHEMBL13012320 0.94 CA2 (0.62) CA2CA9CA1CA12CA14
Bromide SCHEMBL3738017 0.94 CA2 (0.61) CA2CA9CA1CA12CA14
Bromide SCHEMBL3738018 0.94 CA2 (0.61) CA2CA9CA1CA12CA14
SCHEMBL13012323 0.91 CA2 (0.47) CA2CA9CA1CA12CA14
SCHEMBL14615288 0.88 CA2 (0.63) CA2CA9CA1CA12CA14
SCHEMBL4554833 0.86 CA2 (0.39) CA2CA9CA1CA12CA14
SCHEMBL13078014 0.84 CA2 (0.46) CA2CA9CA1CA12CA14
SCHEMBL3737819 0.84 CA2 (0.54) CA2CA9CA1CA12CA14
SCHEMBL13012727 0.79 CA2 (0.68) CA2CA9CA1CA12CA14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8354092-B2 Development of molecular imaging probes for carbonic anhydrase-IX using click chemistry SIEMENS MEDICAL SOLUTIONS USA, INC. (US) 2013-01-15 US disclosed
EP-2468734-A1 Development of molecular imaging probes for carbonic anhydrase-IX using click chemistry Siemens Medical Solutions USA, Inc. (US) 2012-06-27 EP disclosed
US-20100317842-A1 Development of Molecular Imaging Probes for Carbonic Anhydrase-IX Using Click Chemistry SIEMENS MEDICAL SOLUTIONS USA, INC. (US) 2010-12-16 US disclosed
US-7829063-B2 Development of molecular imaging probes for carbonic anhydrase-IX using click chemistry SIEMENS MEDICAL SOLUTIONS USA, INC. (US) 2010-11-09 US disclosed
US-20090123372-A1 DEVELOPMENT OF MOLECULAR IMAGING PROBES FOR CARBONIC ANHYDRASE-IX USING CLICK CHEMISTRY SIEMENS MEDICAL SOLUTIONS USA, INC. 2009-05-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100317842-A1 Development of Molecular Imaging Probes for Carbonic Anhydrase-IX Using Click Chemistry CA9, CA4, CA13 CA2 9/4885CA9 1/4885CA1 5/4885
US-20090123372-A1 DEVELOPMENT OF MOLECULAR IMAGING PROBES FOR CARBONIC ANHYDRASE-IX USING CLICK CHEMISTRY CA9, CA4, CA13 CA2 9/4885CA9 1/4885CA1 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.